Does Oral Sildenafil (Viagra) Decrease Mean Pulmonary Artery Pressure After Cardiac Surgery?

NCT ID: NCT00334490

Last Updated: 2015-07-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-03-31
• Study Completion Date: 2009-05-31

Brief Summary

Post-operative pulmonary hypertension is a risk factor for right ventricular failure and an increasing cause of morbidity and mortality in patients undergoing high-risk cardiac surgery. Several treatments have been used to treat and reduce post operative pulmonary hypertension. Unfortunately none of these treatments are approved for use in this condition and only one (inhaled nitric oxide) is specific enough to pulmonary hypertension to not cause dangerous low blood pressure in the rest of the body. Sadly, inhaled nitric oxide is difficult and expensive to use, and can cause lung damage. Sildenafil citrate is quite specific to the lung vessels, is easy to administer and does not easily cause low blood pressure in other areas of the body. We hypothesize that oral sildenafil 12.5mg will decrease the baseline (pre-dose) mPAP by at least 20% compared with a placebo.

Detailed Description

Sildenafil citarte is a selective pulmonary vasodilator without profound effects on systemic hemodynamics making it an attractive option for treating post operative pulmonary hypertension in the cardiac surgical patients. It is inexpensive and feasible to administer. Intravenous as well as oral doses have been shown to reduce the mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR) in animal models as well as in clinical trials with adults with primary pulmonary hypertension and children after cardiac surgery . However, no data exists to support the safety and efficacy of Sildenafil citrate in the adult cardiac surgical population. The purpose of this study is to further investigate the potential role of Sildenafil citrate to treat post operative pulmonary hypertension in the cardiac population.

Conditions

Pulmonary Hypertension

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

1

Oral Sildenafil 12.5 mg

Group Type: ACTIVE_COMPARATOR

Sildenafil

Intervention Type: DRUG

12.5 mg Sildenafil once with optional second dose

Sildenafil

Intervention Type: DRUG

12.5 mg orally once with optional second dose

2

Placebo in 5 mls distilled water

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Oral Placebo in 5 mls distilled water

Interventions

Sildenafil

12.5 mg Sildenafil once with optional second dose

Intervention Type: DRUG

Sildenafil

12.5 mg orally once with optional second dose

Intervention Type: DRUG

Placebo

Oral Placebo in 5 mls distilled water

Intervention Type: DRUG

Other Intervention Names

Viagra; Viagra; Viagra

Eligibility Criteria

Inclusion Criteria

• 18 years of age or older
• Scheduled for or has recently undergone a primary or re-do cardiac surgical procedure including coronary artery bypass graft surgery (CABG), heart valve replacement or repair, ascending aortic replacement or repair or any combinations of these procedures with CPB
• No documented allergy to sildenafil citrate
• No clinical or laboratory evidence on routine blood work of significant renal disease or failure. (requires dialysis or a creatinine >/= 200umol/L)
• No clinical or documented laboratory evidence on routine blood work of hepatic disease or failure. (ALT or AST 5x upper limit of normal (ULN) or jaundice)
• The patient if female and of child bearing age is not known to be pregnant.
• No documented history of severe chronic respiratory disease defined as an FEV/VC1< 50% predicted.
• Not currently enrolled as an active participant in another clinical trial of a medical therapy or device.
• No documented stroke or transient ischemic attack within 6 months of study participation
• No documented critical carotid artery stenosis (>70%)
• No retinitis pigmentosa.
• The patient has authorized his/her consent to participate in this trial pre-operatively OR consent to participation is granted on the patient's behalf by a substitute decision maker pre or post operatively.

POST-OPERATIVELY

• A pulmonary arterial catheter (swan-ganz catheter) is insitu.
• The patient has a mPAP measurement of >/= 25mmHg for at least 1 hour.
• The patient has a mean arterial pressure (MAP) of >/= 65mmHg.
• The patient has a heart rate of greater than 40 and less than 130 beats/minute.
• The patient is intubated and mechanically ventilated as per standard ventilation protocol at St. Michael's Hospital.
• The patient has not received intravenous nitroglycerin or nitroprusside within 1 hour before treatment with study medication.

Exclusion Criteria

POST-OPERATIVELY

• The patient requires nitroglycerin based medications continuously (topical/oral/intravenous)
• The patient has an arterial pH of < 7.30 or ≥ 7.47
• The patient has clinical and or documented laboratory evidence from routine blood work of renal dysfunction or failure. (Doubling of pre-operative creatinine or requiring dialysis is indicative of renal dysfunction.)
• The patient has clinical and or documented laboratory evidence from routine blood work of significant hepatic disease or failure. (ALT or AST 5 times ULN or obvious jaundice will be indicative of liver dysfunction)
• The patient's current medical condition in the opinion of the investigator and/or the patient's attending ICU physician makes him/her inappropriate for participation in this study.
• The patient is currently a participant in a clinical trial of an investigational therapy including a drug or medical device.
• The patient has clinical indications of sepsis defined as 2 of the following five criteria: i) leukocytosis (or) leukopenia: wbc >12 x 109/L (or) <4x109/L (>10% bands also, ii) fever (or) hypothermia (temp >38.5C or <36C), iii) tachycardia, hr > 90 beats/minute, iv) tachypnea, respiratory rate (RR) >18 breaths/minute, v) hypotension, SBP <90 mmHg

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Toronto

OTHER

Sponsor Role: collaborator

Unity Health Toronto

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David Mazer, MD

Role: PRINCIPAL_INVESTIGATOR

Unity Health Toronto

Locations

St. Michael's Hospital

Toronto, Ontario, Canada

Countries

Canada

Other Identifiers

REB 04-093

Identifier Type: OTHER

Identifier Source: secondary_id

091532

Identifier Type: -

Identifier Source: org_study_id